<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Dougherty | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/bakerbulb73/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/bakerbulb73/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Dougherty.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">76619caf72083b84a079b2fb70cd8a72</guid>
				<title>Dougherty posted an update: 48, p = 0.0036), men (χ2 = 17.1, p less then 0.0001), and [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41159/</link>
				<pubDate>Fri, 07 Feb 2025 11:37:28 -0800</pubDate>

									<content:encoded><![CDATA[<p>48, p = 0.0036), men (χ2 = 17.1, p less then 0.0001), and current and former smokers (χ2 = 19.2, p less then 0.0001). Notably, epidermal growth factor receptor (EGFR) mutation-positive lung cancer patients with high PAK1 expression showed higher mortality rates than those with low PAK1 expression (91.3% vs. 62.5%, p = 0.02). Therefore, PAK1 o&hellip;<span class="activity-read-more" id="activity-read-more-41159"><a href="http://www.nationalboardinstitute.com/activity/p/41159/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">0a28b228498806ada05ca55d476394cb</guid>
				<title>Dougherty posted an update: depressive symptoms at t



 (β=-.11; P=.02), but web-based [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/39298/</link>
				<pubDate>Wed, 05 Feb 2025 12:25:17 -0800</pubDate>

									<content:encoded><![CDATA[<p>depressive symptoms at t</p>
<p> (β=-.11; P=.02), but web-based message production at t</p>
<p> did not impact t</p>
<p> depressive symptoms (β=.12; P=.34). Web-based message consumption had a larger effect (β=-.11; P=.02) than offline support networks (β=-.08; P=.03) in reducing older adults&#8217; depressive symptoms over time. Higher baseline depressive sym&hellip;<span class="activity-read-more" id="activity-read-more-39298"><a href="http://www.nationalboardinstitute.com/activity/p/39298/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">1dfb92c59041dc60a56e844c422977f8</guid>
				<title>Dougherty posted an update: Death's legal definition must be responsive to advances in [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36822/</link>
				<pubDate>Sun, 02 Feb 2025 12:05:18 -0800</pubDate>

									<content:encoded><![CDATA[<p>Death&#8217;s legal definition must be responsive to advances in technology, and it must delineate between life and death. But where to draw the line is difficult to determine. Death&#8217;s current legal definition requires irreversible cessation of cardiorespiratory function or irreversible cessation of all brain function. But technology can often restore&hellip;<span class="activity-read-more" id="activity-read-more-36822"><a href="http://www.nationalboardinstitute.com/activity/p/36822/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">25c1b7952106d1c64de0c5b65a29fa7f</guid>
				<title>Dougherty posted an update: Testing used in screening, diagnosis and follow-up of [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34209/</link>
				<pubDate>Thu, 30 Jan 2025 12:07:21 -0800</pubDate>

									<content:encoded><![CDATA[<p>Testing used in screening, diagnosis and follow-up of COVID-19 has been a subject of debate. Several organisations have developed formal advice about testing for COVID-19 to assist in the control of the disease. We collated, delineated and appraised current worldwide recommendations about the role and applications of tests to control&hellip;<span class="activity-read-more" id="activity-read-more-34209"><a href="http://www.nationalboardinstitute.com/activity/p/34209/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">360a17e0762a1d3b2d0e4753d944e21a</guid>
				<title>Dougherty posted an update: A Correction to this paper has been published [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/32176/</link>
				<pubDate>Tue, 28 Jan 2025 18:01:40 -0800</pubDate>

									<content:encoded><![CDATA[<p>A Correction to this paper has been published https//doi.org/10.1038/s41467-020-20152-w.Acridone based synthetic and natural products with inherent anticancer activity advancing the research and generating a large number of structurally diversified compounds. In this sequence we have designed, synthesized a series of tetracyclic acridones with&hellip;<span class="activity-read-more" id="activity-read-more-32176"><a href="http://www.nationalboardinstitute.com/activity/p/32176/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">3b8a00e6469c92afa48f392cbbcfa016</guid>
				<title>Dougherty became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/32066/</link>
				<pubDate>Tue, 28 Jan 2025 17:51:34 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>